Wells Fargo upgraded C.R. Bard (NYSE:BCR) from Market Perform to Outperform in a report released today.
- Updated: September 16, 2016
Wells Fargo has upgraded C.R. Bard(NYSE:BCR) from Market Perform to Outperform in a statement released on 9/16/2016.
Previously on 9/15/2016, Evercore ISI released a statement on C.R. Bard(NYSE:BCR) upped the target price from $0.00 to $235.00 that indicated a possible upside of 0.08%.
Showing a price of $223.63, C.R. Bard (NYSE:BCR) traded 3.25% higher on the day. The last stock price close is up 3.45% relative to the two hundred day average, compared with the S&P 500 which has fallen -0.01% over the same time period. The company has been tracking to a 50-day average of $219.98 and two hundred day moving average of $216.50. 660,450 shares of the stock traded hands, up from ann average trading volume of 438,609
Recent Performance Graphic:
C.R. Bard has a one-year low of $172.21 and a 52 week high of $239.43 with a price-earnings ratio of 52. C.R. Bard’s market capitalization is currently $0.0.
Also covering C.R. Bard’s target price, a total of 14 analysts have reported on the company. The consensus target stock price is $226.21 with two firms rating the stock a strong buy, four firms rating the stock a buy, 14 analyts rating the stock a hold, 0 rating the company to underperform, and finally 0 brokeragesrating the stock as sell.
Brief Synopsis About C.R. Bard (NYSE:BCR)
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, and urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.